---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000036"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:35:45.231105+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Q1 net loss $6.7M, cash $411.6M; advancing Duchenne pipeline despite clinical hold

## Summary
- Cash, cash equivalents and marketable securities $411.6M at March 31, 2023, up from $188.7M at Dec 31, 2022.
- Collaboration revenue from Vertex deal $25.3M in Q1; net loss improved to $6.7M from $21.7M in Q1 2022.
- Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; eligible for up to $485M milestones plus royalties.
- ENTR-601-44 IND on clinical hold with FDA; pursuing global healthy volunteer trial initiation in 2023.
- ENTR-601-45 selected as second Duchenne candidate; IND submission planned for Q4 2024.

## SEC filing metadata
- accession: 0001689375-23-000036
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/0001689375-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/trda-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000036
- JSON: https://secwatch.observer/filing/0001689375-23-000036.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000036.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported first quarter ending March 31, 2023 results: revenue $25.3 million, net income ($6.7) million.
  - Period: first quarter ending March 31, 2023
  - Revenue: $25.3 million
  - Net income: ($6.7) million
  - Result: reported results
  source text: development of EEV-therapeutic candidates targeting Duchenne as well as other indications beyond neuromuscular diseases. Collaboration Revenue: Collaboration revenue was $25.3 million for the first quarter of 2023 following the closing of the Vertex Agreement in February 2023. There was no collaboration revenue in the first quarter of 2022. Research &
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000036/0001689375-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.